Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective

GLP-1: Effects in Humans

FDA-Approved GLP-1 RAs

GLP-1 RAs and HbA1c Head-to-Head Trials

Tolerability of GLP-1 RAs

GLP-1 RAs in Development

ITCA 650 Exenatide

ITCA 650 Continuous Delivery of Exenatide

SUSTAIN-1 Once-Weekly Semaglutide Monotherapy

Patients Achieving < 7.0% and ≤ 6.5% HbA1c Target at Week 30

Patients Achieving HbA1c < 7 Patients Achieving HbA1c < 7.0% Without Severe Hypoglycemia and No Weight Gain at Week 30

ITCA 650: FREEDOM-1 Trial

CVOTs for GLP-1 RAs

Medication Adherence Scope of the Problem

Only About One-Third of Patients Are Adherent to GLP-1 RAs

Patient Challenges With GLP-1 RAs and Success of Treatment

Where Will These Emerging GLP-1 RAs Fit Into Clinical Practice in the Future?

Concluding Remarks